Christophe Le Tourneau

Head of Early Phase Clinical Trials

Institut Curie

France

Research Interests

Explore related searches

Professors in France Professors in Medical Imaging Medical Imaging professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Christophe Le Tourneau is the Head of Early Phase Clinical Trials at Institut Curie in France. His research focuses on oncology, particularly in the areas of head and neck cancers, personalized therapy, and clinical trial methodologies. Recent publications include significant studies on the use of pembrolizumab in various phases of head and neck cancer treatment, as well as the assessment of innovative study designs in personalized oncology. He is actively engaged in exploring the efficacy of novel therapeutic strategies and biomarker-driven approaches in cancer management.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (21)

Hisham Mehanna

University of Birmingham

UNITED KINGDOM

Christophe Le Tourneau

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design

Biomarkers and Prognostic Stratification of Squamous Cell Carcinoma of the Oral Cavity in Young Adults: how to personalize therapeutic management?

Modified study designs to expand treatment options in personalised oncology: a multistakeholder view

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study

Proton therapy and/or helical tomotherapy for locally advanced sinonasal skull base adenoid cystic carcinoma: Focus on experience of the Institut Curie and review of literature

First‐line cetuximab + platinum‐based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real‐world observational study—ENCORE

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial

Ethical considerations for precision psychiatry

Collaborators (21)

Hisham Mehanna

François Bertucci

Nicolas Servant

Lioe-Fee de Geus-Oei

Lucia Valmaggia

Mirko Manchia

isabelle ray coquard

Floris van Velden

Anthony Kong

Åslaug Helland

Benoit You

Kevin Harrington

Wyanne Noortman

Anthony Gonçalves

Maud Kamal

Jean-Yves Blay

Robert Ferris

Makoto Tahara

Christophe Deroose

Dennis Vriens

Christiane Woopen

Make your next move.